

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
（深圳市海普瑞藥業集團股份有限公司）
(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock code: 9989)

INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2022



FINANCIAL HIGHLIGHTS



	For the six months ended June 30,	
	2022	
	RMB'000	*B'000*
	3,756,335	- %
	1,218,477	- %
	511,140	- %

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

F... ...8... ... J... 30, 2022

	Six months ended June 30,	
	2022	
	RMB'000	*B'000*
	(unaudited)	( )
PROFIT FOR THE PERIOD	**510,404**	
OTHER COMPREHENSIVE INCOME		
( ).		
	127,108	( )
	14,161	( )
	141,269	( )
( ) ( ).		
( )	**(6,330)**	
	55,720	
( )	**49,390**	
( )	**190,659**	( )
( )	**701,063**	
	701,162	
	(99)	( )

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

J 30, 2022

		June 30, 2022 *RMB'000* (unaudited)	*B'000* ( )
NON-CURRENT ASSETS			
		2,524,576	
		233,185	
		2,265,521	
		467,037	
		1,084,027	
		489,917	
		976,721	
		126,183	
		255,796	
		8,422,963	
CURRENT ASSETS			
		5,750,897	
	11	**1,784,190**	
		17,016	
		501,140	
		47,506	
		1,344,007	
		(1,940)	
		30,284	
		1,110,000	
		2,355,848	
		12,938,948	
CURRENT LIABILITIES			
	12	**554,266**	
		466,099	
		51,355	
		484,116	
		5,368,927	
		125,102	
		40,199	
		27,798	
		7,117,862	

INTERIM CONDENSED CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

J 30, 2022

		June 30, 2022	
		RMB'000	*B'000*
		(unaudited)	( )
NET CURRENT ASSETS		**5,821,086**	
TOTAL ASSETS LESS CURRENT LIABILITIES		**14,244,049**	
NON-CURRENT LIABILITIES			
		1,593,832	
		17,460	
		311,933	
		64,111	
		9,558	
		101,162	
		2,098,056	
Net assets		**12,145,993**	
EQUITY			
	13	**1,467,296**	
		10,566,836	
		12,034,132	
		111,861	
		12,145,993	

MANAGEMENT DISCUSSION AND ANALYSIS

Overview

(CDMO)

( )

( ) (API)

( )

( )

(R&D)

- (Cytovance)

(SPL)

Business Review









H1710





Outlook









Financial Review

Re en e

	For the six months ended June 30,				
	2022 Sales amount RMB'000 (unaudited)	2022 % of Revenue	2021 Sales amount RMB'000 (unaudited)	2021 % of Revenue	Year-on-year increase/ decrease (%)
	3,268,855	87.0%		%	- %
	1,601,941	42.6%		%	%
	1,610,312	42.9%		%	%
( )	56,602	1.5%		%	(%)
	468,180	12.5%		%	- %
( )	19,300	0.5%		%	- %
Total	3,756,335	100.0%	3,111,164	100.0%	20.7%

( )

( )



Cost of sales

Operating Costs

Gross profit

	For the six months ended June 30,			
	2022 Gross profit RMB'000 (unaudited)	2022 Gross profit margin (%)	2021 Gross profit RMB'000 (unaudited)	2021 Gross profit margin (%)
	1,023,644	31.3%		%
	545,970	34.1%		%
	479,295	29.8%		%
	(1,621)	(2.9%)		%
	176,030	37.6%		%
	18,803	97.4%		%
Total	**1,218,477**	**32.4%**	**976,907**	**31.4%**

Finance Costs

Taxation

Profit Attributable to Equity Holders of the Company

Non-IFRS Measures

IFRSs



	For the six months ended June 30,	
	2022	
	RMB'000	*B'000*
	(unaudited)	( )
	511,140	
	(62)	
	14,393	
	(5,220)	
	(797)	( )
	(1,449)	( )
	(22)	( )
	6,843	
	504,297	

Earnings per Share



Liquidity and Financial Resources

Treas r Policies



Liq idit and Financial Reso rces

Capital Str ct re

Pledge of Assets

Contingent Liabilities

Asset-liabilit Ratio

Interest Rate Risk

Indebtedness

	As at June 30, 2022 *RMB'000* (unaudited)	
	6,962,759	
	128,960	
	7,091,719	
	(30,287)	
	7,061,432	

	As at June 30, 2022 *RMB'000* (unaudited)	
	5,368,927	
	483,803	
	630,692	
	479,337	
	6,962,759	

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

F [illegible] 8 [illegible] J [illegible] 30, 2022

1. Corporate Information

(**PRC**)

(**Hong Kong Stock Exchange**) ( )

(**Group**)

2.1 Basis of Preparation

(**IAS**)

(**IFRSs**)-

2.2 Changes in Accounting Policies and Disclosures

(.)



(.)



( )

( )

–

–

3. Operating Segment Information

( )

( )

( )

( )

Segment re en e and res lts

[illegible]

Segment	Finished dose pharmaceutical products *RMB'000*	Active pharmaceutical ingredients *RMB'000*	CDMO *RMB'000*	Others *RMB'000*	Total *RMB'000*
[illegible]	1,601,941	1,610,312	468,180	75,902	3,756,335
[illegible]	1,079,759	1,633,576	1,361	222,999	2,937,694
	2,681,700	3,243,888	469,541	298,901	6,694,029
[illegible]					(2,937,694)
					3,756,335
[illegible]	453,645	576,233	177,455	51,446	1,258,778
[illegible]					(40,301)
[illegible]					140,353
[illegible]					(243,563)
[illegible]					(298,078)
[illegible]					(9,252)
[illegible]					(892)
[illegible]					(123,014)
[illegible]					(54,990)
[illegible]					629,041

					B'000

Geographical information

( )

	For the six months ended June 30, 2022	
	RMB'000	*B'000*
	(unaudited)	( )
	61,857	
	675,882	
	1,906,724	
	319,804	
	792,068	
	3,756,335	

( )

	As at June 30, 2022	
	RMB'000	*B'000*
	(unaudited)	( )
	2,863,063	
	3,506,849	
	131,054	
	329,177	

Information abo t major c stomers

%

%

4. Revenue

Re en e from contracts ith c stomers

( )

For the six months ended June 30, 2022 (unaudited)

Segment	Finished dose pharmaceutical products *RMB'000*	Active pharmaceutical ingredients *RMB'000*	CDMO *RMB'000*	Others *RMB'000*	Total *RMB'000*
Type of goods or services					
	1,601,941	1,610,312	–	56,602	3,268,855
	–	–	468,180	–	468,180
	–	–	–	19,300	19,300
	1,601,941	1,610,312	468,180	75,902	3,756,335
Timing of revenue recognition					
	1,601,941	1,610,312	–	56,602	3,268,855
	–	–	107,029	5,837	112,866
	–	–	361,151	13,463	374,614
	1,601,941	1,610,312	468,180	75,902	3,756,335

	B'000	*B'000*	*B'000*	*B'000*	*B'000*
Type of goods or services					
Timing of revenue recognition					

	For the six months ended June 30, 2022 *RMB'000* (unaudited)	*B'000*
	5,407	
	259,409	
	264,816	

(..)

CD

(**FFS**)

(

)

	As at June 30, 2022 *RMB'000* (unaudited)	*B'000*
	1,020,314	

5. Other Income and Gains

	For the six months ended June 30,	
	2022	
	RMB'000	*B'000*
	(unaudited)	( )
Other income		
	29,000	
	1,036	
	13,358	
	4,843	
	–	
	48,237	
Other gains		
	102,886	( )
	2,255	
	(12,155)	
	(2,194)	( )
	(62)	
	–	
	1,386	
	92,116	( )
	140,353	

6. Finance Costs

	For the six months ended June 30,	
	2022	
	RMB'000	*B'000*
	(unaudited)	( )
	68,995	
	40,433	
	1,902	
	11,684	
	123,014	

7. Profit before Tax

	For the six months ended June 30,	
	2022	
	RMB'000	*B'000*
	(unaudited)	( )
	2,224,286	
	313,572	
	107,863	
	19,045	
	25,559	
	79,104	
	4,987	
	320,423	
	57,449	
	3,189	
	(29,000)	( )
	123,014	
	(4,843)	( )
	–	( )
	(102,886)	
	(2,255)	( )
	2,194	
	12,155	( )
	(47)	( )
	–	
	9,252	
	3,793	

8. Income Tax Expense

	For the six months ended June 30,	
	2022	
	RMB'000	*B'000*
	(unaudited)	( )
	36,810	
	57,684	
	9,141	
	7,667	
	111,302	
	12,387	( )
	(5,421)	
	369	
	7,335	( )
	118,637	

9. Dividends

	For the six months ended June 30,	
	2022	
	RMB'000	*B'000*
	(unaudited)	( )
	51,355	

( ) ( )

( ) ( )

10. Earnings per Share Attributable to Ordinary Equity Holders of the Parent

	For the six months ended June 30, 2022 *RMB'000* (unaudited)	*B'000* ( )
	511,140	

	For the six months ended June 30, 2022 (unaudited) ( )
	1,467,296,204

11. Trade and Bills Receivables

	As at June 30, 2022 *RMB'000* (unaudited)	*B'000* ( )
	1,865,656	
	12,937	
	(94,403)	( )
	1,784,190	

	As at June 30, 2022 *RMB'000* (unaudited)	[illegible] *B'000* [illegible]
[illegible]	**1,745,500**	[illegible]
	63,003	[illegible]
	63,555	[illegible]
	6,535	[illegible]
	1,878,593	[illegible]
[illegible]	**(94,403)**	[illegible]
	1,784,190	[illegible]

	As at June 30, 2022 *RMB'000* (unaudited)	[illegible] *B'000* [illegible]
[illegible]	**86,299**	[illegible]
[illegible]	**6,905**	[illegible]
[illegible]	**–**	[illegible]
[illegible]	**1,199**	[illegible]
	94,403	[illegible]

12. Trade Payables

	As at June 30, 2022 *RMB'000* (unaudited)	
	554,266	

	As at June 30, 2022 *RMB'000* (unaudited)	
	551,662	
	1,457	
	287	
	860	
	554,266	

13. Share Capital

	As at June 30, 2022 *RMB'000* (unaudited)	
	1,467,296	

Use of Proceeds from the H Share Listing of the Company



Use of proceeds (RMB million)	Net proceeds from Global Offering	Utilised as at June 30, 2022	Remaining amount	Expected time of use

Significant Investments

%

Material Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

Events after the Reporting Period

Employee and Remuneration Policy

(,)

( )-

Purchase, Sale or Redemption of Listed Securities

Compliance with Corporate Governance Code

(**Corporate Governance Code**)-

Compliance with the Model Code for Securities Transactions by Directors of Listed Issuers

Review of Interim Results by the Audit Committee

Interim Dividends

Publication of Interim Results Announcement and Interim Report 2022

Appreciation

Shenzhen Hepalink Pharmaceutical Group Co., Ltd.
Li Li